ICECURE MEDICAL LTD (ICCM)
IL0011224156 - Common Stock
ICECURE MEDICAL LTD
NASDAQ:ICCM (5/17/2024, 11:09:04 AM)
1.05
+0.03 (+2.94%)
Company Profile
IceCure Medical Ltd. is a commercial stage medical device company. The firm operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
Company Info
ICECURE MEDICAL LTD
7 Ha'eshel St., PO Box 3163
CAESAREA
P: 97246230333
CEO: EYAL SHAMIR
Employees: 65
Website: https://icecure-medical.com/
ICCM News
10 days ago - IceCure MedicalIndependent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally/PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation...
17 days ago - USA News GroupAs Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response/PRNewswire/ -- USA News Group – An alarming rise in early-onset cancers has medical experts very concerned, as cancer cases in younger people are rising...
17 days ago - USA News GroupAs Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response/CNW/ -- USA News Group – An alarming rise in early-onset cancers has medical experts very concerned, as cancer cases in younger people are rising sharply. In...
a month ago - IceCure MedicalIceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast CancerData presentation at highly influential American Society of Breast Surgeons ("ASBrS") Annual Meeting by Dr. Richard Fine wins Scientific Impact Award as voted...
a month ago - InvestorPlaceICCM Stock Earnings: Icecure Medical Meets EPS, Beats Revenue for Q4 2023ICCM stock results show that Icecure Medical met analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
a month ago - IceCure MedicalIceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance/PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation...
ICCM Twits
Here you can normally see the latest stock twits on ICCM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
